2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations

A method of preventing excessive estrogenic uterine stimulation in a mammal, the method comprising administering to a mammal in need thereof an estrogen and an effective amount of a compound having the structure:

• wherein:
• R1 is selected from H, OH or the C1-C4 esters or alkyl ethers thereof, or halogen;
• R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
• X is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, or halogen;
• n is 2 or 3;
• Y is the moiety:
• R7 and R8 are selected independently from H, C1-C6 alkyl, or combined by —(CH2)p—, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, —CO2H, —CN, —CONH(C1-C4)alkyl, —NH3, C1-C4 alkylamino, di(C1 -C4)alkylamino, —NHSO2(C1-C4)alkyl, —NHCO(C1-C4)alkyl, and —NO2;
• or a pharmaceutically acceptable salt thereof.